Mechanism of anti-HIV activity of negatively charged albumins: Biomolecular interaction with the HIV-1 envelope protein gp120

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 5, 1996, Pages 419-429

  Kuipers, M E ^a   Huisman, J G ^b   Swart, P J ^a   De Bethune M P ^c,d   Pauwels, R ^c,d   Schuitemaker, H ^b   De Clercq, E ^c   Meijer, D K F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d TIBOTEC BVBA   (Belgium)

Author keywords

Binding affinity; gp120; Negatively charged albumins; Polyanionic proteins; Synthetic peptides; V3 loop

Indexed keywords

ALBUMIN; GLYCOPROTEIN GP 120;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ZEA MAYS;

EID: 0029995129     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199604150-00001     Document Type: Article

References (49)

1. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-7.
2. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984;312:767-8.
3. Baba M, Pauwels P, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1988;85:6132-6.
4. + cells. Science 1988;240:646-9.
5. Mbemba E, Czyrski JA, Gattegno L. The interaction of a glycosaminoglycan, heparin, with HIV-1 major envelope glycoprotein. Biochim Biophys Acta 1992;1180:123-9.
6. Baba M, De Clercq E, Schols D, et al. Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity. J Infect Dis 1990;161:208-13.
7. Swart PJ, Meijer DKF. Negatively-charged albumins: a novel class of polyanionic proteins with a potent anti-HIV activity. Antiviral News 1994;2:69-71.
8. Jansen RW, Molema G, Pauwels R, Schols D, De Clercq E, Meijer DKF. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol Pharmacol 1991;39:818-23.
9. Jansen RW, Schols D, Pauwels R, De Clercq E, Meijer DKF. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 1993;44: 1003-7.
10. Meshcheryakova D, Andreev S, Tarasova S, et al. CD4- derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Mol Immunol 1993;30:993-1001.
11. Callahan LN, Phelan M, Mallinson M, Norcross MA. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 1991;65: 1543-50.
12. Batinic D, Robey FA. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 1992;267:6664-71.
13. Lucey DR, Vancott TC, Loomis LD, et al. Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop). J Acquir Immune Defic Syndr 1993;6:994-1001.
14. Moore JP, Nara PL. The role of the V3 loop of gp120 in HIV infection. AIDS 1991;5:s21-33.
15. Bergeron L, Sullivan N, Sodroski J. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J Virol 1992;66:2389-97.
16. Pinter A, Honnen WJ, Tilley SA. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. J Virol 1993; 67:5692-7.
17. Autiero M, Abrescia P, Dettin M, Di Bello C, Guardiola J. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-envelope protein. Virology 1991;185:820-8.
18. Haïdar M, Gluckman JC, Gattegno L. Mannosyl/N-acetyl- β-D-glucosaminyl binding properties of the envelope glyco- protein of human immunodeficiency virus type 2. Glycobiology 1992;2:429-35.
19. Gattegno L, Sadeghi H, Saffar L, et al. N-acetyl-β-D- glucosaminyl-binding properties of the envelope glycoprotein of human immunodeficiency virus type 1. Carbohydr Res 1991;213:79-93.
20. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-60.
21. Schuitemaker H, Kootstra NA, Groenink M, De Goede REY, Miedema F, Tersmette M. Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. AIDS Res Hum Retrovir 1992;8:1679-82.
22. Pless DP, Lennarz WJ. Enzymatic conversion of proteins to glycoproteins. Proc Natl Acad Sci USA 1977;74:134-8.
23. Deakin H, Ord MG, Stocken LA. Glucose-6-phosphate dehydrogenase' activity and thiol content of thymus nuclei from control and x-irradiated rats. Biochem J 1963;89:296- 304.
24. Schwartz BA, Gray GR. Proteins containing reductively aminated disaccharides: synthesis and characterization. Arch Biochem Biophys 1977;181:542-9.
25. Kataoka M, Tavassoli M. Synthetic neoglycoproteins: a class of reagents for detection of sugar-recognizing substances. J Histochem Cytochem 1984;32:1091-4.
26. Kuipers ME, Swart PJ, Hendriks MMWB, Meijer DKF. Optimization of the reaction conditions for the synthesis of neoglycoprotein-AZT-monophosphate conjugates. J Med Chem 1995;38:883-9.
27. Jansen RW, Molema G, Harms G, et al. Formaldehyde treated albumin contains monomeric and polymeric forms that are differently cleared by endothelial and Kupffer cells of the liver: evidence for scavenger receptor heterogeneity. Biochem Biophys Res Commun 1991;180:23-32.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
29. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 1956;28:350-6.
30. Habeeb AFSA. Determination of free amino groups in proteins by trimtrobenzenesulfonic acid. Anal Biochem 1966; 14:328-36.
31. 131I labelled human growth hormone of high specific radio- activity. Biochem J 1963;89:114-23.
32. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660-72.
33. Molema G, Jansen RW, Pauwels R, De Clercq E, Meijer DKF. Targeting of antiviral drugs to T-4 lymphocytes: anti- HIV activity of neoglycoprotein-AZTMP conjugates in vitro. Biochem Pharmacol 1990;40:2603-10.
34. Groenink M, Fouchier RAM, Broersen S, et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993;260:1513-6.
35. Fouchier RAM, Groenink M, Kootstra NA, et al. Pheno- type-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-7.
36. Jansen RW, Molema G, Ching TL, et al. Hepatic endocytosis of various types of mannose-terminated albumins: What is important, sugar recognition, net charge or the combination of these features? J Biol Chem 1991;266:3343-8.
37. Callahan L. HIV-1 virion-cell interactions: an electrostatic model of pathogenicity and syncytium formation. AIDS Res Hum Retrovir 1994;10:231-3.
38. Yahi N, Fantini J, Mabrouk K, et al. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages. J Virol 1994;68:5714- 20.
39. Witvrouw M, Desmyter J, De Clercq E. Antiviral portrait series. IV. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem Chemother 1994;5:345-59.
40. Müller R. Calculation of average antibody affinity in anti- hapten sera from data obtained by competitive radioimmunoassay. J Immunol Meth 1980;34:345-52.
41. Chiou S-H, Freed EO, Panganiban AT, Kenealy WR. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function. AIDS Res Hum Retrovir 1992;8:1611-18.
42. Pal R, DeVico A, Rittenhouse S, Sarngadharan MG. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type-1 by soluble CD4 and the lectin succinyl con-A. Virology 1993;194:833-7.
43. Gordon LM, Curtain CC, Mccloyn V, Kirkpatrick A, Mobley PW, Waring AJ. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin. AIDS Res Hum Retrovir 1993;9:1145-56.
44. Harrop HA, Coombe DR, Rider CC. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, effect potentiated by CD4 binding. AIDS 1994;8:183-92.
45. Gorny MK, Xu J-Y, Karwowska S, Buchbinder A, Zolla- Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993;150:635-43.
46. White-Scharf ME, Potts BJ, Smith LM, Sokolowski KA, Rusche JR, Silver S. Broadly neutralizing monoclonal anti- bodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 1993;192:197-206.
47. Vancott TC, Bethke FR, Polonis VR, et al. Dissociation rate of antibody-gp120 binding interactions is predictive of V3- mediated neutralization of HIV-1. J Immunol 1994;153:449- 59.
48. Benjouad A, Mabrouk K, Gluckman JC, Fenouillet E. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein. FEBS Lett 1994;341:244-50.
49. Rider CC, Coombe DR, Harrop HA, et al. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 1994;33:6974-80.